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C AS E S TU DY
A 26 year-old female (G3P1) had a D&E in March, 2010 for a blighted ovum.
The diagnosis on the uterine contents at an outside institution was placental
site trophoblastic tumor. No follow up care was obtained. Four months
later (July, 2010), the patient presented to her OB-GYN stating that she had
missed a period and had a positive home pregnancy test. An ultrasound
examination failed to identify a fetus, and the patient was referred to TJUH.
At Jefferson an MRI showed a poorly defined uterine mass that extended
into the myometrium. The slides from the original D & E were reviewed by
the Pathology Department at Jefferson, and the diagnosis of placental site
trophoblastic tumor was confirmed. A total abdominal hysterectomy was
then performed.

Histologic examination showed both masses to be a placental site
trophoblastic tumor with areas of polygonal intermediate type trophoblastic cells and many scattered enlarged multi-nucleated cells. The tumor
infiltrated deeply into the myometrium of the left wall of the lower uterine
segment (essentially transmural infiltration).

Staining of cytoplasm for human placental lactogen (20x)

There is a prominent mass in the uterine fundus (MRI; sagittal view)

(September, 2010) The specimen was received in surgical pathology for
frozen section consultation. Opening of the uterus revealed two distinct
lesions, a 4.0 x 3.5 x 2.5 cm mass in the posterior wall of the lower uterine
segment and a 6.5 x 5.3 x 4.0 cm mass in the anterior myometrium.
Sectioning of each mass revealed variegated, tan-yellow, and focally hemorrhagic cut surfaces.

Tumor cells invading the myometrium (H&E; 20x)
The neoplastic trophoblastic cells showed diffuse cytoplasmic staining for
human placental lactogen and scattered cytoplasmic staining for human
chorionic gonadotrophin. The tumor cells were negative for PLAP. Ki-67
positivity was present in 30% of the tumor cells.

Placental site trophoblastic tumors are rare, slow growing malignant tumors
derived from the intermediate cytotrophoblast cells of the placenta.1 They
account for <0.2% of all gestational trophoblastic disease. Metastases are
present at the time of initial diagnosis in 30-53% of cases. Common sites of
metastasis include the lungs, pelvis and lymph nodes. Less common sites
include the CNS, kidney and liver. EMA-EP (etoposide, methotrexate and
actinomycin D alternating with etoposide and cisplatin) is the preferred adjuvant chemotherapy.
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